Methods and compositions for treating conditions
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/07
A61K-038/08
A61K-038/10
출원번호
US-0582008
(2009-10-20)
등록번호
US-8530432
(2013-09-10)
발명자
/ 주소
Skubatch, Hanna
출원인 / 주소
NeoPro Labs, LLC
대리인 / 주소
Wilson Sonsini Goodrich & Rosati
인용정보
피인용 횟수 :
0인용 특허 :
18
초록▼
The invention relates to compositions comprising of SEQ NO: 1-244, 248-249, and any homologs, analogs, and fragments thereof. Such compositions can be used to treat, prevent, and modulate pain, inflammation, and metabolic processes in various organisms including plants and animals. Such compositions
The invention relates to compositions comprising of SEQ NO: 1-244, 248-249, and any homologs, analogs, and fragments thereof. Such compositions can be used to treat, prevent, and modulate pain, inflammation, and metabolic processes in various organisms including plants and animals. Such compositions can be formulated with an acceptable pharmaceutical excipient for administration to a human or a plant. The compositions can be administered topically or for systemic use.
대표청구항▼
1. An isolated polypeptide having a sequence consisting of SEQ ID NO: 153. 2. An isolated polypeptide comprising SEQ ID NO: 154. 3. An isolated polypeptide comprising SEQ ID NO: 160, wherein the isolated polypeptide comprises less than 10 amino acid residues. 4. The isolated polypeptide of claim 3,
1. An isolated polypeptide having a sequence consisting of SEQ ID NO: 153. 2. An isolated polypeptide comprising SEQ ID NO: 154. 3. An isolated polypeptide comprising SEQ ID NO: 160, wherein the isolated polypeptide comprises less than 10 amino acid residues. 4. The isolated polypeptide of claim 3, wherein the isolated polypeptide comprises less than 9 amino acid residues. 5. The isolated polypeptide of claim 3, wherein the isolated polypeptide comprises less than 8 amino acid residues. 6. The isolated polypeptide of claim 3, wherein the isolated polypeptide has a sequence consisting of SEQ ID NO: 160. 7. An isolated polypeptide comprising SEQ ID NO: 156, wherein the isolated polypeptide comprises less than 10 amino acid residues. 8. The isolated polypeptide of claim 7, wherein the isolated polypeptide comprises less than 9 amino acid residues. 9. The isolated polypeptide of claim 7, wherein the isolated polypeptide comprises less than 8 amino acid residues. 10. The isolated polypeptide of claim 7, wherein the isolated polypeptide has a sequence consisting of SEQ ID NO: 156. 11. A pharmaceutical formulation comprising the isolated polypeptide of claim 3, 4, 5, or 6, and a pharmaceutical excipient. 12. The pharmaceutical formulation of claim 11, wherein the pharmaceutical excipient is for dermal delivery, oral delivery or subcutaneous delivery. 13. A pharmaceutical formulation comprising the isolated polypeptide of claim 7, 8, 9, or 10, and a pharmaceutical excipient. 14. The pharmaceutical formulation of claim 13, wherein the pharmaceutical excipient is for dermal delivery, oral delivery or subcutaneous delivery. 15. A pharmaceutical formulation comprising the isolated polypeptide of claim 2 and a pharmaceutical excipient. 16. The pharmaceutical formulation of claim 15, wherein the pharmaceutical excipient is for dermal delivery, oral delivery or subcutaneous delivery. 17. A pharmaceutical formulation comprising the isolated polypeptide of claim 1 and a pharmaceutical excipient. 18. The pharmaceutical formulation of claim 17, wherein the pharmaceutical excipient is for dermal delivery, oral delivery or subcutaneous delivery.
Sette, Alessandro; Sidney, John; Southwood, Scott; Vitiello, Maria A.; Livingston, Brian D.; Celis, Esteban; Kubo, Ralph T.; Grey, Howard M.; Chesnut, Robert W., Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions.
Vertesy Lszl (Eppstein/Taunus DEX) Geisen Karl (Frankfurt am Main DEX) Riess Gnther J. (Frankfurt am Main DEX) Sauber Klaus (Bad Soden am Taunus DEX), Insulin derivatives, a process for the preparation thereof, the use thereof, and a pharmaceutical formulation containing.
Bridon, Dominique P.; Ezrin, Alan M.; Milner, Peter G.; Holmes, Darren L.; Thibaudeau, Karen, Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.